Navigation Links
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Date:6/23/2009

VIENNA, Austria, June 23 /PRNewswire/ -- MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity Award competition, hosted by the industry magazine Boerse-Express and Junge Industrie. The award recognised the long-standing association between the German venture fund and the Austrian biotechnology company as well as a euro 430 million deal between AFFiRiS and GSK Biologicals.

Last Tuesday MIG Fonds and AFFiRiS AG were awarded first place in the Venture Capital and Private Equity (VC/PE) awards by the Austrian industry magazine Boerse-Express.com and their co-sponsors Junge Industrie. The winners were chosen following a special selection process that combines the perspectives of the magazine's readers and selected experts, who evaluate corporate success stories from different perspectives. This year, an investment relationship that has been fruitful for both venture partners was recognised and the importance of VC financing for the start-up period of innovative businesses was thereby recognised.

Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC/PE awards "have a very special significance for the capital investment market in Austria because they demonstrate the vital function of VC in the development of promising high-tech businesses. In our case, three years ago MIG Fonds started to invest a total of euro 11.5 million. Without this capital, our licensing deal with GSK Biologicals three years later would not have been possible. This deal is for up to euro 430 million in upfront and milestone payments for our Alzheimer's vaccines. MIG Fonds' decision to invest has therefore already been beneficial for everyone involved."

Based on the MIG Fonds investment, AFFiRiS AG was able to develop its AFFITOME(R) technology, which delivers innovative vaccines with very specific properties. The firm has already announced the development of candidates for therapeutic vaccines against Alzheimer's, Parkinson's and atherosclerosis - in other words, against diseases that have so far seemed unsuitable for treatment by vaccination, but that represent markets worth billions. Vaccine candidates for four further undisclosed chronic diseases are currently being developed by AFFiRiS AG.

Asked about the success story of AFFiRiS AG and the current award, Andreas Höfler of Alfred Wieder AG said: "We are very proud of this award. Good investment tends to not only promote advances in technology, but also to promote individuals and aims that are as visionary as they are clear. Our MIG fund managers also pay particular attention to ensuring that the target markets of our potential investees are of a sufficient size, and that the businesses we finance have the potential to become international market leaders. We recognised this potential in AFFiRiS three years ago - the first big pharma deal and the current award confirm our initial analysis."

About AFFiRiS AG (as at June 2009)

AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical solution and that have considerable market potential. Alzheimer's disease is currently the principal indication and two potential products are in the final stages of clinical phase I studies. In October 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The contract anticipates milestone-dependent payments of up to euro 430 million. AFFiRiS currently employs 50 highly qualified staff and recently added an additional 1,100 sqm to its premises at the St. Marx campus in Vienna, Austria (http://www.affiris.com).

    Contact at AFFiRiS AG:

    Agnes Meyer
    Karl-Farkas-Gasse 22
    1030 Vienna
    Austria
    T +43-1-798-15-75 - 390
    E agnes.meyer@affiris.com

    Copy-editing & distribution:

    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    Austria
    T +43-1-505-70-44
    E contact@prd.at



'/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
5. The next generation: nanomagnets could replace semiconductors
6. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Campbell Alliance Named Best Place to Work by Triangle Business Journal
10. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):